Save the Children!
No Shots for Tots
Call to Action
The public comment period is open to provide feedback on the FDA’s evaluation of Pfizer’s experimental C-19 mRNA injections for children aged 6 months to 4 years. I could go on and on about how unconscionable this is but my purpose with this post is for you to provide your own comments. Stand for Health Freedom has an excellent summary of points that you can use to make your comments. Please click here to provide a public comment before February 10th. Thanks so much for helping to protect the children!
Below is the public statement I provided today. Feel free to use a few details but please make it your own. I purposely did not discuss VAERS, the ineffectiveness of the jab, or the fact that children have strong immune systems and their risk from COVID is incredibly low. If any agency states that OMICRON is more dangerous to children they are flat out lying as this is physiologically impossible. Children have a lower expression of ACE2 receptors and are less likely to get infected, less likely to spread the virus, and much less likely to have severe symptoms. Oh, and don’t even get me started on how effective, robust, broad, and durable natural immunity is, which is clearly superior to artificial immunity.
My Public Comment
The COVID-19 experimental biological products are touted as safe and effective, yet the FDA and Pfizer are currently fighting in court (again) to delay releasing the safety data. What is there to hide? Where is the transparency? Why can’t independent scientists review the safety data? Is an immunobridging control group in a different age category really sufficient for this important data? What about the lop-sided data exclusions that overwhelm the effect size in Pfizer's pivotal clinical studies or the unblinding of the control group? If you look at the original data in the supplemental file, these injected products cause a significant increase in overall mortality.
We need to acknowledge that clinical trials are ongoing and some are scheduled to be concluded within two years, other studies will take longer. The novel mRNA experimental products have not been studied in children under age 5, pregnant and breastfeeding women, immunocompromised patients, patients with co-morbidities (COPD, diabetes, chronic neurological disease, and cardiovascular disorders), patients with autoimmune or inflammatory disorders, interactions with other vaccines, or any long term safety studies. In addition, the risks of anaphylaxis, myocarditis and pericarditis, and vaccine-associated enhanced (VAED) and vaccine-associated enhanced respiratory disease (VAERD) have not been properly assessed.
Reproductive toxicity has not been properly evaluated. There have been NO studies for genotoxicity and NO studies for carcinogenicity. Animal studies are incomplete and inadequate.
From the Nonclinical Evaluation Report and biodistribution study:
“Parturition: One ~ in the BNT162b3 group was euthanized on LDl showing hunched posture, pale, marked piloerection, bleeding at the vulva, distended/purple abdomen. One ~ each in the BNT162bl and BNT162b3 groups were euthanized due to all stillborn pups or total litter death. No macroscopic findings were noted in maternal necropsy.”
Fetal malformations/variations were found in the pups of dams in the treatment groups.
There has been insufficient testing of the novel lipid nanoparticles; 2-[(Polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) and ((4-hydroxybutyl)azanediyl) bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) are novel excipients and are not listed on the TGA' s ingredient database.
ALC-0315 (the ester formulation) was minimally metabolized and only 1% was excreted
ALC-0159 (the amide formulation) was more completely metabolized and only 50% was excreted
These novel LNP have very long elimination half-lives, especially ALC-0315 (the ester formulation), which is extremely concerning.
These data prove that the LNP are distributed systemically, not broken down efficiently, and stay in the body for a long period of time. Not only that, but the spike (S) protein expression can occur anywhere in the body, reaches high levels of expression, and may be of long duration (possibly mimicking the length of time antibody titers remain elevated.)
The biodistribution study is also very alarming because it shows that these LNPs accumulate not only at the injection site but also immediately to the liver, spleen, kidneys, and lymph nodes with rising concentrations (at 48 hours, the longest timepoint measured) in the ovaries, bone marrow, thyroid gland, pituitary gland, heart, and lungs.
The S1 subunit of the spike glycoprotein that the mRNA instructs cells to produce has been shown to cause hypercoagulation, microclots, inflammation, and structural changes to fibrin(ogen), complement 3, and prothrombin in several studies. Additionally, the S1 (spike subunit) can dysregulate tight junctions and cross the blood-brain barrier, blood-air barrier, blood-testis barrier, and blood-placental barrier. It can also cause downregulation of ACE2 receptors, impair mitochondrial function, increase oxidative stress, impede DNA damage repair, and inhibit V(D)J recombination in vitro.
Please do not allow our children to be guinea pigs for these experiments!
Nonclinical Evaluation Report: BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATY ™) 2021. Submission No: PM-2020-05461-1-2 Sponsor: Pfizer Australia Pty Ltd. https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf
Clinical Safety Summary: file:///C:/Users/Zana%20Carver/Desktop/VAERS%20Analysis/STN-125742_0_0-Section-2.7.4-summary-clin-safety.pdf
Clinical Overview: https://phmpt.org/wp-content/uploads/2021/12/STN-125742_0_0-Section-2.5-Clinical-Overview.pdf
Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. 2021. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Bioscience reports 41(8):BSR20210611.
Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, Zhang Y, Yin Q, Cho Y, Andrade L et al. . 2021. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circulation research 128(9):1323-1326.
Raghavan S, Kenchappa DB, Leo MD. 2021. SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity. Frontiers in Cardiovascular Medicine 8(582).
Jiang H, Mei Y-F. 2021. SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. Viruses 13(10):2056.